Redeye provides an update following Optomed’s Q2 report. Although sales and EBIT came in lower than anticipated, we argue that the investment case remains intact. We highlight upcoming reports that may potentially show sales related to the US rollout of Aurora AEYE. Furthermore, we have made only minor estimate changes, leaving the fair value range unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/